Peptide Impurities: Types, Origins and Detection

Peptide impurities fall into two broad groups: process-related species, such as residual solvents, reagents and starting materials, and product-related species, which are structurally similar to the target peptide and include deletion fragments, oxidation products and aggregates. This is the classification used in the European Medicines Agency guideline on synthetic peptides. The sections below set out how each type forms, why it matters to experimental results, which analytical methods detect it, and what a headline purity percentage does and does not establish.

All products discussed on this site are supplied strictly for laboratory research. They are not for human or veterinary use.

Overview: where impurities come from

Most research peptides are made by solid-phase peptide synthesis (SPPS), in which amino acids are coupled one at a time to a resin-bound chain. Each cycle comprises deprotection of the N-terminus (commonly Fmoc removal), coupling of the next protected amino acid, and washing. A peptide of 30 residues therefore involves roughly 30 coupling and 30 deprotection steps, and any incomplete step leaves a population of chains that differ from the target. After the final cleavage from the resin and removal of side-chain protecting groups, the crude product is purified, typically by preparative liquid chromatography, and then freeze-dried.

Impurities arise at three stages:

• Synthesis: incomplete or excess coupling, incomplete deprotection, racemisation.
• Cleavage and purification: side reactions with scavengers and cleavage reagents, counterion incorporation, residual solvents.
• Storage and handling: oxidation, deamidation, hydrolysis, aggregation and cyclisation reactions.

The review by D'Hondt and colleagues, Related impurities in peptide medicines, organises related impurities into groups tied to these origins. The remainder of this article follows the same logic.

Process-related impurities

Process-related impurities are not variants of the peptide itself. They are substances introduced by, or left over from, manufacture.

Residual solvents and reagents

Solvents used in coupling, washing and cleavage (for example dimethylformamide, dichloromethane, acetonitrile and diethyl ether) can persist in the lyophilised powder at trace levels. Coupling reagents, bases and scavengers, together with their by-products, may also remain if purification and washing are inadequate. These species are usually quantified by gas chromatography or related techniques, not by the peptide HPLC trace that produces a purity percentage.

Counterions

Trifluoroacetic acid (TFA) is routinely used in cleavage and in reversed-phase mobile phases, so many research peptides are supplied as TFA salts. The counterion contributes to the powder mass and can interfere with cell-based assays at sufficient concentration. Exchange to acetate or chloride is a standard remedy; our guide to validated peptide counterion exchange describes the procedure and the checks that should follow.

Starting-material impurities

The protected amino acids used for synthesis carry their own impurity profile. The D'Hondt review lists free amino acids or amino acid derivatives, and contaminating amino acids other than the intended residue, among starting-material-related impurities. Because a contaminated building block is incorporated at every position where it is used, its effect is multiplied across the synthesis.

Product-related impurities formed during synthesis

These species share most of the target's structure, which is why they are the hardest to remove and the most likely to retain biological activity.

Deletion sequences

A deletion peptide lacks one or more residues. It forms when Fmoc deprotection is inefficient: the N-terminus remains blocked, the next amino acid is not coupled, and in later cycles the chain continues without the missing residue. Difficult sequences, such as those containing hydrophobic stretches or beta-branched residues, are prone to on-resin aggregation that lowers deprotection and coupling efficiency. A single deletion can shift a peptide's mass by one residue, which makes it detectable by mass spectrometry, but it often elutes very close to the target on HPLC.

Truncated sequences

Truncation occurs when a chain is permanently terminated, often by capping, so that synthesis stops early and the peptide is shorter at the C-terminal side of its growth direction. Truncated chains are typically more easily separated than single deletions because the length difference is larger.

Insertion sequences

Insertions arise from excess amino-acid reagent. The D'Hondt review attributes them to over-activated or surplus amino acid that couples a second time, adding an extra residue. Like deletions, they differ from the target by one residue mass.

Diastereomers from racemisation

Activation of an amino acid for coupling can invert its alpha-carbon stereochemistry, converting an L-residue into its D-form. The product is a diastereomer: identical mass to the target, different three-dimensional structure. Cysteine and histidine are particularly susceptible. Because the mass is unchanged, mass spectrometry alone cannot distinguish a diastereomer from the target, and resolution depends on the chromatographic method. The ACS-published LC-MS characterisation workflow discusses structural isomers and stereoisomers specifically for this reason.

Protection adducts

When side-chain deprotection is inefficient, residual protecting groups remain on the peptide. Reactive species generated during cleavage can also alkylate sensitive residues such as tryptophan, methionine, tyrosine and cysteine. The resulting adducts show a characteristic positive mass shift and generally elute later than the target on reversed-phase columns.

Dimers and disulfide-linked species

Peptides containing free cysteines can form homodimers and heterodimers through disulfide bonds. A 2025 investigation of peptide pools reported that the most frequent and perhaps unexpected impurities were such dimers, caused by the free cysteines (Bosc-Bierne et al., listed among the search results for this topic). Where a sequence carries more than one cysteine, intramolecular and intermolecular disulfide scrambling should be anticipated.

Degradation products formed after synthesis

The D'Hondt review identifies a second impurity group resulting from typical peptide degradation mechanisms: beta-elimination, diketopiperazine formation, pyroglutamate formation and succinimide formation. These occur during processing and storage, and their rate depends on sequence, pH, temperature, moisture and time.

Oxidation deserves emphasis because it is common and preventable. Peptides exposed to oxygen and light during storage oxidise at susceptible side chains, and methionine-containing sequences are a frequent example. Storage of lyophilised material at low temperature, protected from light and moisture, and minimal freeze-thaw cycling of reconstituted solutions, reduce the rate of these reactions. Reconstitution volumes can be planned with the peptide dilution calculator so that only the quantity required for a defined period is prepared.

Why impurities matter for experimental results

Impurities are not inert. Many product-related species retain partial or full activity at the target receptor, so a deletion peptide or an oxidised variant can act as an agonist, a partial agonist or an antagonist, and the measured response then reflects a mixture instead of a single compound.

The published literature documents consequences for data quality. D'Hondt and colleagues note that related impurities can strongly influence initial functionality studies and cause erroneous conclusions, so their control is critical. A study of impurities in commercial synthetic peptides found that peptide cross-contamination can generate false-positive results in T-cell assays and lead to misinterpretation of research or clinical-trial data. The same authors recommend that research and clinical assessment laboratories perform appropriate biological as well as biochemical quality assurance and quality control on all peptides.

Three practical consequences follow:

1. Potency and dose-response curves: if the active peptide is 90% of the powder and 10% is a mixture of related species, the nominal concentration overstates the target and the curve may shift or change shape.
2. Assay artefacts: counterions, residual solvents and endotoxin-like contaminants can produce cytotoxicity or signalling that is attributed incorrectly to the peptide.
3. Reproducibility: batch-to-batch variation in the impurity profile is a recognised source of irreproducible results between laboratories.

Detection and characterisation by impurity type

No single technique reveals every impurity class. The method has to match the question.

The FDA's document on common deficiencies in comparative peptide assessments recommends orthogonal chromatographic methods and UHPLC-HRMS/MS for identifying peptide-related impurities and matching peaks between products. It also states thresholds for generic synthetic peptides: each peptide-related impurity at or above 0.10% is to be identified, and no new impurity above 0.5% is to be shown. These are regulatory expectations for a specific United States approval pathway, not standards that apply automatically to research-grade material, but they illustrate the level of characterisation that is technically achievable.

The ACS-published workflow proposes liquid chromatography coupled with mass spectrometry as the core strategy for identifying synthetic-peptide impurities, including structural isomers and stereoisomers. For a comparison of the two commonly offered techniques, see our notes on HPLC versus LC-MS and on HPLC versus mass spectrometry for researchers. A practical walk-through of identity confirmation is available in the mass spec peptide verification guide.

Reading a certificate of analysis

A certificate of analysis (COA) is only as informative as the data behind it. When reviewing one, check the following:

• The chromatogram is attached, not just the percentage, and the integration wavelength and gradient are stated.
• The mass spectrum shows the observed mass matching the theoretical mass within instrument tolerance.
• The batch or lot number on the COA matches the vial.
• The testing laboratory is identified and independent of the manufacturer.
• The report distinguishes HPLC purity from net peptide content.

The three checks labs should verify on receipt expand on this routine, and the guide to spotting counterfeit peptides in Australia covers documentation that does not stand up to scrutiny.

What a purity percentage does and does not establish

A figure such as 99% purity usually refers to the area of the main peak as a proportion of total peak area in a single RP-HPLC run at a single wavelength, commonly 214 or 220 nm. It tells the reader less than it appears to for several reasons.

• Co-elution: a deletion peptide or diastereomer that elutes under the main peak is counted as target. An orthogonal method or mass spectrometry is needed to reveal it.
• Invisible components: water, counterions, residual solvents and inorganic salts do not absorb at the detection wavelength, so they do not reduce the HPLC purity figure even when they make up a large share of the powder mass.
• Purity versus content: HPLC purity describes the proportion of peptide-related material that is target. Net peptide content describes how much of the vial mass is peptide at all. A vial can be 99% pure by HPLC and still contain substantially less than its labelled mass of active peptide.
• Identity: purity does not confirm identity. A pure peak of the wrong peptide still reads as pure.

For context, the review by Vergote and colleagues, Related impurities in peptide medicines, states that the total level of related impurities in pharmaceutical-grade synthetic peptide active ingredients should generally not exceed 5%. Purification is the main control: as De Luca and colleagues observe in their review of downstream processing of therapeutic peptides, polishing steps are challenging because product-related impurities resemble the target peptide, and preparative liquid chromatography remains the most flexible and widely used method.

The term "pharmaceutical grade" adds a further layer of ambiguity; our article on what the term means in Australia and the risk-based comparison of GMP and research peptides set out the distinctions. Sterility and visual checks address different risks again; see the sterility release checklist and the note on visual inspection and its blind spot.

Regulatory context in Australia

The Therapeutic Goods Administration has issued a warning on the risks of importing unapproved peptide products. It states that it is not possible to know whether such products contain other contaminants or toxins, and that they may pose serious health risks. The warning concerns unapproved products and underlines the importance of documented provenance, batch-level analytical data and domestic supply chains for any material entering a laboratory. Research peptides are intended for in vitro and laboratory investigation only.

Perspective

In our experience of supplying laboratories, the most frequent source of disagreement between a stated purity and a laboratory's own results is not fraud but incomplete reporting: a single-wavelength HPLC percentage presented without the mass spectrum, without the chromatogram and without a statement of net peptide content. We therefore regard a batch-specific COA, issued by an independent testing laboratory and traceable to the vial, as the minimum documentation a researcher should expect. Purity above 99% is meaningful only when the identity is confirmed by mass and the main peak has been examined for co-eluting species.

We also consider that impurity control does not end at dispatch. Oxidation and moisture uptake are storage-dependent, which is why we dispatch from Melbourne within one business day and avoid customs holds that can leave temperature-sensitive material in transit for extended periods. Researchers should still document receipt conditions, store lyophilised material cold and protected from light, and retest when a result is unexpected.

— Dr. Authur

Sourcing documented research peptides

Au Peptide Labs stocks research peptides tested independently to 99%+ purity, with a verifiable COA for every batch, shipped from Melbourne in discreet packaging. Catalogue categories include Metabolic and GLP-1, Recovery and Repair, GH Secretagogues, Cognitive and Sleep, Longevity and Cellular and Lab Supplies. Express Post is available for $10. Custom and bulk orders can be arranged on request through the main site. All products are for laboratory research use only.

Frequently asked questions

What are the impurities in peptides?

They fall into process-related impurities (residual solvents, reagents, starting-material contaminants) and product-related impurities (deletions, insertions, diastereomers, protection adducts, oxidation products and aggregates). The first group originates from manufacture, and the second consists of molecules structurally close to the target peptide.

What are the main types of peptide impurities in synthesis?

The principal synthesis-related types are deletion peptides from inefficient Fmoc deprotection, insertion peptides from excess amino-acid reagent, diastereomers from racemisation and adducts from inefficient side-chain deprotection. Degradation products such as pyroglutamate, diketopiperazine and succinimide forms appear later, during processing and storage.

What purity should research peptides be?

The appropriate threshold depends on the assay. Pharmaceutical-grade peptide active ingredients are generally expected to contain no more than 5% total related impurities, and sensitive receptor or cell-based work commonly specifies purity above 95% with confirmed identity. A figure above 99% supported by the chromatogram, mass spectrum and net peptide content is the most defensible documentation.

Can HPLC alone detect all impurities?

No. HPLC with UV detection can miss co-eluting species, diastereomers with similar retention and non-absorbing components such as salts and water. Orthogonal chromatography and high-resolution mass spectrometry are used to close these gaps.

Sources

• EMA: Guideline on the development and manufacture of synthetic peptides
• Related impurities in peptide medicines (PubMed)
• Related impurities in peptide medicines (ScienceDirect)
• Peptide impurities in commercial synthetic peptides
• Characterization of synthetic peptide therapeutics using LC-MS
• FDA: Common deficiencies associated with comparative peptide assessments
• Downstream processing of therapeutic peptides
• TGA warning on the risks of importing unapproved peptide products

Recommended

• Peptide Visual Inspection in Australia: 4 Red Flags, One Blind Spot
• Oxidation of peptides: mechanisms, detection and prevention
• 5 Checks Labs Use to Spot Counterfeit Peptides in Australia
• Triage and Prevent Peptide Vial Contamination in Labs: When to Discard